Telluride Asset Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Telluride Asset Management’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	$213K	Buy	+900	New	+$237K	0.18%	193

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Telluride Asset Management's ICPT Position: Q2 2014 in Review

Telluride Asset Management opened a new position in Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2014: 900 shares worth $213K. The stake represents 0.18% of the portfolio and ranks #193 among its holdings.

167 funds tracked by Wall St. Rank hold ICPT as of Q2 2014.

Telluride Asset Management held 900 shares of Intercept Pharmaceuticals, Inc. worth $213K as of Q2 2014.
Intercept Pharmaceuticals, Inc. was a new Telluride Asset Management position in Q2 2014.
Intercept Pharmaceuticals, Inc. made up 0.18% of Telluride Asset Management's portfolio in Q2 2014, its #193 holding.
167 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2014.

Based on Telluride Asset Management's 13F filing for Q2 2014, filed 14 Aug 2014.